End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.63 CNY | +2.35% | -1.05% | -25.73% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm trades with high earnings multiples: 33.28 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.73% | 245M | - | ||
+7.93% | 41.28B | B- | ||
-20.24% | 22.66B | B- | ||
-13.76% | 13.54B | B- | ||
-9.15% | 10.37B | B+ | ||
+23.55% | 8.43B | C+ | ||
+7.38% | 6.89B | C+ | ||
-26.87% | 5.46B | C | ||
-22.19% | 3.6B | B+ | ||
-21.64% | 3.38B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301237 Stock
- Ratings Hangzhou Heshun Technology Co.,LTD.